Fiskars is highly exposed to the US through Fiskars BA.
Titania AB (”Titania” eller ”Bolaget”) meddelade den 11 april år 2025 att Bolaget har tecknat ett 10...
Redeye provides an in-depth review of Episurf Medical’s Q1 report and events during and after the qu...
Redeye comments on Lipum’s announcement of the finalized Clinical Study Report (CSR) for the phase I...
Slightly softer sales and outlook (-5% vs. ABGSCe in Q4) We cut '25e-'26e sales by 9-8%, EBIT 24-15%...
Redeye is optimistic about the start of a well-sized phase II study in patients with Dengue fever an...
Redeye updates on Invisio ahead of Q1-results (due 6 May) where we expect continued solid YoY growth...
Redeye comments on Carasent’s Q1 report, showing solid ARR growth yet somewhat higher OPEX.
Incap had already anticipated a slow start for 2025, and now the entire EMS sector is holding its br...
Q1e: Clean paper EBIT of ~PLN 15m Price hikes, but demand soft Fair value range of SEK 34-75 Our ea...
Redeye shares its preview of BONESUPPORT’s Q1 2025 results, due April 24.
Redeye comments on SenzaGen’s expanded testing portfolio, introducing the EpiSensA method, which com...
Genetic Analysis AS (”Genetic Analysis” or ”the Company”) has developed the GA-map®, a platform for ...
Redeye reviews its valuation of IRLAB following the missed top-line readout with pirepemat in PD-fal...
Redeye sees the acquisition of Welotec as a strategically sound move with relatively low risks.
Q1e: clean EBIT of ~SEK -45m, Q2 likely better Pulp prices up, but futures point down Fair value ran...
Redeye gives its view on mezagitamab, whose phase III start triggered a milestone payment to BioInve...
Q1 likely flat, limited uptick in Q2e Targets challenging - likely to land below Recovery postponed ...
We believe organic growth could be negative y/y for Q1 2025.
Global efterfrågan driver tillväxtmöjligheter LifeClean verkar på en växande marknad där skärpta kra...
